BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today announced the completion of a U.S. clinical study, conducted by Ora, Inc. Andover, MA, designed to compare widely used benchmark tests for dry eye with its TeaRx diagnostic parameters that test components of tear film.
from The Medical News http://ift.tt/1tZQRtt
from The Medical News http://ift.tt/1tZQRtt
No comments:
Post a Comment